^
    PD-L1 expression
    Gastroesophageal Junction Adenocarcinoma
    nivolumab + ipilimumab
    Sensitive: C1 - Off-label
    ASCO 2022 - 3 days - (New C3)
    PD-L1 expression
    Gastric Cancer
    durvalumab + AZD6738
    Sensitive: C3 – Early Trials
    ASCO 2022 - 3 days - (New C3)
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    tislelizumab + ZW25
    Sensitive: C3 – Early Trials
    ASCO 2022 - 3 days - (New C3)
    HER-2 positive
    Gastric Cancer
    tislelizumab + ZW25
    Sensitive: C3 – Early Trials
    ASCO 2022 - 3 days - (New C3)
    HER-2 expression
    Gastroesophageal Junction Adenocarcinoma
    KN026
    Sensitive: C3 – Early Trials
    ASCO 2022 - 3 days - (New C3)
    HER-2 expression
    Gastric Cancer
    KN026
    Sensitive: C3 – Early Trials
    ASCO 2022 - 3 days - (New C3)
    VSNL1 underexpression + CD44 underexpression
    Gastric Cancer
    paclitaxel
    Sensitive: B - Late Trials
    Sci Rep - 1 week - (New B)
    CLDN18.2 positive
    Gastric Cancer
    CT041
    Sensitive: C2 – Inclusion Criteria
    Nat Med - 2 weeks - (New C3)
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    Gastric Adenocarcinoma
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive: A1 - Approval
    HER-2 positive
    Gastric Cancer
    fam-trastuzumab deruxtecan-nxki
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    fam-trastuzumab deruxtecan-nxki
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    TPF
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    TPF
    Sensitive: A1 - Approval
    HER-2 positive
    Gastric Cancer
    pembrolizumab + trastuzumab
    Sensitive: A1 - Approval
    HER-2 negative + PD-L1 expression
    Gastroesophageal Junction Adenocarcinoma
    nivolumab
    Sensitive: A1 - Approval
    HER-2 negative + PD-L1 expression
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab
    Sensitive: A1 - Approval
    HER-2 negative + PD-L1 expression
    Gastric Cancer
    nivolumab
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    trastuzumab
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Trazimera (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Trazimera (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Ontruzant (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Ontruzant (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Ogivri (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Ogivri (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Kanjinti (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Kanjinti (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Herzuma (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Herzuma (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    trifluridine / tipiracil
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    trifluridine / tipiracil
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    ramucirumab
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    capecitabine
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    ramucirumab
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Zercepac (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Zercepac (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastric Cancer
    Zercepac (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    MSI-H/dMMR
    Gastric Cancer
    pembrolizumab
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    Ontruzant (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    Kanjinti (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    Ogivri (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab + trastuzumab
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    disitamab vedotin
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    disitamab vedotin
    Sensitive: A1 - Approval
    HER-2 positive
    Gastric Cancer
    trastuzumab
    Sensitive: A2 - Guideline
    HER-2 negative
    Gastric Cancer
    cisplatin + capecitabine
    Sensitive: A2 - Guideline
    HER-2 negative
    Gastroesophageal Junction Adenocarcinoma
    cisplatin + capecitabine
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    DOF
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    TCF
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    TCF
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    FP
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    CaT
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    FP
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    FOLFIRI
    Sensitive: A2 - Guideline
    HER-2 negative
    Gastroesophageal Junction Adenocarcinoma
    CAPOX
    Sensitive: A2 - Guideline
    HER-2 negative
    Gastroesophageal Junction Adenocarcinoma
    5-fluorouracil + oxaliplatin
    Sensitive: A2 - Guideline
    HER-2 negative
    Gastroesophageal Junction Adenocarcinoma
    FP
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    capecitabine
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    5-fluorouracil
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    DP
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    5-fluorouracil
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    5-fluorouracil + irinotecan
    Sensitive: A2 - Guideline
    HER-2 negative
    Gastric Cancer
    cisplatin + 5-fluorouracil
    Sensitive: A2 - Guideline
    HER-2 negative
    Gastric Cancer
    CAPOX
    Sensitive: A2 - Guideline
    HER-2 negative
    Gastric Cancer
    5-fluorouracil + oxaliplatin
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    paclitaxel + 5-fluorouracil
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    paclitaxel + capecitabine
    Sensitive: A2 - Guideline
    TMB-H
    Gastric Cancer
    pembrolizumab
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    FLOT
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    FLOT
    Sensitive: A2 - Guideline
    HER-2 positive
    Gastroesophageal Cancer
    trastuzumab
    Sensitive: A2 - Guideline
    PD-L1 expression
    Gastric Adenocarcinoma
    pembrolizumab
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    cisplatin + irinotecan
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    irinotecan
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    docetaxel
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    docetaxel + irinotecan
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    cisplatin + docetaxel
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    carboplatin + paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    CAPOX
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    5-fluorouracil + oxaliplatin
    Sensitive: A2 - Guideline
    MSI-H/dMMR
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    cisplatin + capecitabine
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    5-fluorouracil + irinotecan
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    irinotecan
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    docetaxel
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    docetaxel + irinotecan
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    IP
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    5-fluorouracil + oxaliplatin
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    capecitabine + oxaliplatin
    Sensitive: A2 - Guideline
    NTRK3 fusion
    Gastroesophageal Junction Adenocarcinoma
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK2 fusion
    Gastroesophageal Junction Adenocarcinoma
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK1 fusion
    Gastroesophageal Junction Adenocarcinoma
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK3 fusion
    Gastroesophageal Junction Adenocarcinoma
    entrectinib
    Sensitive: A2 - Guideline